Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Revenues:"We expect development revenues in 2013 will be comprised of approximately $19 million in committed R&D funding and license fee revenues from existing collaborations, and we anticipate $6 million to $9 million in additional license fees, R&D funding, milestones and cost reimbursements," Rogers noted. 

    "We forecast the vast majority of 2013 commercial revenues to be based on existing collaboration agreements.  While it remains difficult to forecast commercial revenues due to uncertainties around product launch timing, the number of product lines that will include our flavor ingredients, and other factors, we are currently estimating 2013 commercial revenues to be approximately $6 million.

    "2013 should prove to be a transitional year for Senomyx as we implement our direct sales strategy," Rogers stated.  "While direct sales are not expected to yield significant results in 2013, our goal is for direct sales to be a key driver of meaningful commercial revenues in future years.

    Expenditures:"Looking at expenditures, as we consider our resource requirements over the next several years for R&D, G&A and Commercial Operations, excluding the cost of commercial revenues, we expect we will be able to manage our expenses to be generally in-line with our 2013 expense guidance range, subject to quarterly fluctuations and increases for inflation.
    With respect to the expanded commercial organization activities in support of our direct sales strategy, many of the functions will be handled by existing Senomyx personnel.  In other cases, such as supply chain and account management, we will add dedicated resources to support these functions.
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
    (Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
    (Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
    (Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
    ... , FORT WORTH, Texas , ... Board: WNDM), announced today that it is nearing the completion of its ... first distributor in that country.  Numerous physicians in the nation have ... with its speed and efficacy in the management of diabetic ulcers ...
    ... , SAN FRANCISCO , Jan. 13 ... fully configurable system that allows users to design and deploy ... and cost of other providers. Leveraging a background of more ... the Clinical Trial industry, endpoint designed PULSE to balance speed ...
    ... , ROCHESTER, N.Y. , Jan. ... for biomedical research in the U.S. has decelerated and may have even ... today published in the Journal of the American Medical Association . ... began in the 1990,s has ended," said Ray Dorsey , ...
    Cached Biology Technology:Wound Management Technologies, Inc. Rapidly Expands Its International Presence 2Wound Management Technologies, Inc. Rapidly Expands Its International Presence 3Wound Management Technologies, Inc. Rapidly Expands Its International Presence 4endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6
    (Date:10/15/2014)... our ability to assess the pandemic risk from strains ... we must not allow ourselves to become complacent that ... international consortium of scientists. , Influenza pandemics arise when ... yet to develop widespread immunity – spreads in the ... the past 100 years, the worst of which – ...
    (Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
    (Date:10/14/2014)... been millions of years since T. rex ... Ohio University scientists is breathing life back into dinosaurs ... snouts. The research has important implications for how dinosaurs ... enhance the sense of smell and cool their brains. ... University doctoral student Jason Bourke, lead author of the ...
    Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
    ... 13, 2012) The blood-brain barrier is essential for maintaining ... and isolating the brain,s specific hormonal and neurotransmitter activity from ... addition to nerve cells, the brain contains glia cells that ... blood-brain boundary is made by glia joined into an envelope ...
    ... DC - On January 18, 2012, Dr. Peter ... National Homeland Security Research Center in the Office ... Protection Agency, will lead a session titled "National ... national resilience to bioterrorism threats involves maximizing advanced ...
    ... previously un-named species of horse fly whose appearance is dominated ... honour of American pop diva, Beyonc a member of ... single, Bootylicious. , According to the Australian National Insect Collection ... ( Plinthina ) beyonceae , CSIRO,s Bryan Lessard, ...
    Cached Biology News:Brain glia cells increase their DNA content to preserve vital blood-brain barrier 2Fly named in honor of Beyonce 2
    Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
    Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
    PKC Sampler Kit 10 mu g each...
    Purified anti-SOCS3...
    Biology Products: